Meropenem Steriscience (Meropenem)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the transpeptidation step of peptidoglycan synthesis. This inhibition prevents cross‑linking of the cell wall, leading to loss of structural integrity and bacterial cell death. Its stability against most β‑lactamases gives it a wide spectrum of activity.

The dosage of Meropenem Steriscience is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function and local guidelines. Dosing regimens may range from 0.5 g to 2 g administered intravenously every 8 hours, with adjustments required for renal impairment. Exact dosing must be individualized.

Safety data for meropenem in pregnancy and lactation are limited, and the drug is generally classified as use‑only when the potential benefit outweighs the risk to the fetus or infant. Clinicians should evaluate the necessity of therapy and consider alternative agents with established safety profiles. Breastfeeding mothers should discuss potential exposure with their healthcare provider.

To place an order, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Meropenem shares the broad‑spectrum activity of the carbapenem class but offers a slightly higher stability against certain β‑lactamases compared with imipenem and a more favorable safety profile than ertapenem regarding seizure risk. Choice among carbapenems depends on the pathogen susceptibility, infection site, dosing convenience and patient‑specific factors such as renal function.

Meropenem Steriscience should be stored refrigerated at 2 °C to 8 °C, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product label, typically within 24 hours if kept at room temperature, and discarded thereafter.

The drug is supplied as a sterile powder for reconstitution and is administered intravenously over a 15‑ to 30‑minute infusion. Administration should be performed by qualified healthcare personnel using aseptic technique, and infusion rates may be adjusted in patients with renal impairment or at risk of seizures. Compatibility with common IV fluids should be confirmed before mixing.

The most serious adverse events include seizures, especially in patients with renal dysfunction or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis which can lead to life‑threatening diarrhea. Prompt recognition and discontinuation of therapy, along with appropriate supportive care, are essential when these events occur.

Meropenem is contraindicated in individuals with a documented hypersensitivity to meropenem, other carbapenems or any β‑lactam antibiotics. Caution is also advised for patients with a history of severe seizures, uncontrolled epilepsy, or significant renal impairment without dose adjustment. In such cases, alternative antimicrobial agents should be considered.